文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

酪氨酸未磷酸化STAT5与JAK抑制维持造血干细胞

Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition.
PubMed 文献 · Blood Adv · 2025-01-01

该研究探讨STAT5在造血干细胞(HSC)中的功能,发现STAT5缺失导致多系重建与自我更新下降、静息退出减少和分化增加,由经典pSTAT5及非磷酸化uSTAT5功能丧失共同驱动。表达不可磷酸化STAT5突变体或使用JAK1/2抑制剂芦可替尼可限制HSC分化、促进维持并上调干性转录程序。

要点

  • STAT5缺失HSC表现为多系重建与自我更新下降、静息退出减少及分化增加。
  • 不可磷酸化STAT5突变体限制野生型HSC分化、促进维持并上调静息与干性转录程序。
  • 芦可替尼提高uSTAT5:pSTAT5比值,限制小鼠HSC分化与增殖并促进维持。

核心结论

  • pSTAT5与uSTAT5在HSC功能调控中存在此前未认识的相互作用。
  • JAK抑制是体外培养中增强HSC功能的潜在策略。
  • uSTAT5水平升高可能促进JAK抑制剂无法根除骨髓增殖性肿瘤。

研究设计与样本

  • 研究使用STAT5缺陷HSC、不可磷酸化STAT5突变体表达及JAK1/2抑制剂芦可替尼处理,评估小鼠HSC功能。
  • 研究还检测芦可替尼对正常人造血干/祖细胞(HSPC)、钙网蛋白突变小鼠HSC及骨髓纤维化患者HSPC的连续再铺板能力。

主要发现

  • STAT5缺陷HSC表现为多系重建与自我更新下降,同时静息退出减少、分化增加。
  • 该表型由经典pSTAT5信号丧失及缺乏经典酪氨酸磷酸化的STAT5(uSTAT5)所介导的独特转录功能丧失共同驱动。
  • 表达不可磷酸化STAT5突变体限制野生型HSC分化、促进其维持并上调与静息和干性相关的转录程序。
  • 芦可替尼提高uSTAT5:pSTAT5比值,限制小鼠HSC分化与增殖、促进HSC维持并上调干性相关转录程序。
  • 芦可替尼增强正常人造血干/祖细胞、钙网蛋白突变小鼠HSC及骨髓纤维化患者HSPC的连续再铺板能力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adult hematopoietic stem cells (HSCs) are responsible for the lifelong production of blood and immune cells, a process regulated by extracellular cues, including cytokines. Many cytokines signal through the conserved Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in which tyrosine-phosphorylated STATs (pSTATs) function as transcription factors. STAT5 is a pivotal downstream mediator of several cytokines known to regulate hematopoiesis, but its function in the HSC compartment remains poorly understood. In this study, we show that STAT5-deficient HSCs exhibit an unusual phenotype, including reduced multilineage repopulation and self-renewal, combined with reduced exit from quiescence and increased differentiation. This was driven not only by the loss of canonical pSTAT5 signaling, but also by the loss of distinct transcriptional functions mediated by STAT5 that lack canonical tyrosine phosphorylation (uSTAT5). Consistent with this concept, expression of an unphosphorylatable STAT5 mutant constrained wild-type HSC differentiation, promoted their maintenance, and upregulated transcriptional programs associated with quiescence and stemness. The JAK1/2 inhibitor, ruxolitinib, which increased the uSTAT5:pSTAT5 ratio, had similar effects on murine HSC function; it constrained HSC differentiation and proliferation, promoted HSC maintenance, and upregulated transcriptional programs associated with stemness. Ruxolitinib also enhanced serial replating of normal human hematopoietic stem and progenitor cells (HSPCs), calreticulin-mutant murine HSCs, and HSPCs obtained from patients with myelofibrosis. Our results therefore reveal a previously unrecognized interplay between pSTAT5 and uSTAT5 in the control of HSC function and highlight JAK inhibition as a potential strategy for enhancing HSC function during ex vivo culture. Increased levels of uSTAT5 may also contribute to the failure of JAK inhibitors to eradicate myeloproliferative neoplasms.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Williams MJ, Wang X, Bastos HP, et al. Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition. Blood Adv. 2025. PMID: 39374575. doi:10.1182/bloodadvances.2024014046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。